[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ultra-hypofractionated-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ultra-hypofractionated-radiotherapy":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100623398",false,"NCT07396116","Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)","Preoperative Hypofractionated Radiotherapy Combined With Immunotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-02)","FUSION-02","Inclusion Criteria:\n\n* Diagnosis \\& Indication: Primary or recurrent abdominopelvic soft tissue sarcoma. Patients are deemed to have a high probability of R1\u002FR2 resection with upfront surgery and are confirmed to require radiotherapy following Multidisciplinary Team (MDT) discussion.\n* Target Volume: In cases of multifocal disease, all lesions must be safely encompassable within a single radiotherapy target volume.\n* Age: Age ≥ 18 years.\n* Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status 0-2; American Society of Anesthesiologists (ASA) score ≤ 2; patients must be expected to tolerate surgery and radiotherapy.\n* Pathology: Histologically confirmed soft tissue sarcoma.\n* Measurability: Presence of evaluable lesions.\n* Life Expectancy: Life expectancy \\> 5 years.\n* Hematological \\& Hepatic Function: Adequate organ function\n* Renal Function: Adequate renal function defined as Glomerular Filtration Rate (GFR) ≥ 50 ml\u002Fmin (calculated by Cockcroft-Gault formula), and split renal function imaging confirms function in the contralateral kidney.\n* Contraception: Female patients of childbearing potential, or male patients with female partners of childbearing potential, must agree to use effective contraception during the entire treatment period and for 6 months after the last dose.\n* Consent: Signed informed consent form.\n* Follow-up: Capable of complying with follow-up requirements.\n\nExclusion Criteria:\n\n* Significant Comorbidities: Patients with the following concurrent conditions: active hemorrhage, ulceration, intestinal perforation, intestinal obstruction, uncontrolled hypertension, cardiac insufficiency (NYHA Class III-IV), severe hepatic or renal dysfunction (Grade 4), mesenteric ischemia, or severe inflammatory bowel disease (IBD).\n* Excluded Histologies: Other pathological types, including Gastrointestinal Stromal Tumor (GIST), sarcomatoid carcinoma, sarcomas primarily treated with chemotherapy (e.g., rhabdomyosarcoma and PNET), desmoid fibromatosis, and benign tumors.\n* Unresectability: Tumor invasion into critical structures such as the liver, pancreatic head, or abdominal aorta, rendering the tumor deemed unresectable.\n* Prior Radiotherapy: History of prior radiotherapy to the same anatomical region.\n* Distant Metastasis: Presence of distant metastasis (M1) confirmed by comprehensive imaging\u002Fexamination within 4 weeks prior to enrollment.\n* Contraindications to Surgery\u002FProtocol: Presence of other severe medical comorbidities that contraindicate surgery or preclude participation in the study.\n* Planned Neoadjuvant Chemotherapy: Patients scheduled to receive (concurrent) neoadjuvant chemotherapy.\n* Recent Systemic Therapy: Receipt of chemotherapy or other systemic treatments within 4 weeks prior to enrollment.","ALL","18 Years",{"count":19,"type":20},28,"ESTIMATED","INTERVENTIONAL",[23],"NA","To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy combined with immunotherapy followed by surgery for retroperitoneal sarcoma",[26,27,28,29,30],"Soft Tissue Sarcoma (STS)","Retroperitoneal Sarcoma","Immunotherapy","Radiotherapy Side Effect","Ultra-hypofractionated Radiotherapy",[32,33,34,35,36],"hypofractionated radiotherapy","retroperitoneal sarcoma","soft tissue sarcoma","immunotherapy","peri-operative complications","NOT_YET_RECRUITING","2026-02-10",{"date":40,"type":41},"2026-02-12","ACTUAL",{"date":40,"type":20},{"date":44,"type":20},"2028-12-31",{"name":46,"class":47},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",1,{"id":50,"slug":4,"hasResults":10,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100456541","NCT05224934","Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)","Full-target Ultra-hypofractionated Stereotactic Irradiation Orchestrated With Nodule Boost for Retroperitoneal Sarcoma","FUSION-01","Inclusion Criteria:\n\n* Primary soft tissue sarcoma of retroperitoneal or infra-peritoneal spaces of pelvis\n* Sarcoma not originated from bone structure, abdominal or gynecological viscera\n* All disease can be included safely within one radiotherapy field\n* Absence of extension through the sciatic notch or across the diaphragm\n* Histologically proven, excluding the following subtypes: Gastro-intestinal stromal tumors (GIST), rhabdomyosarcoma, PNET or other small round blue cells sarcoma, osteosarcoma or chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma\n* ECOG performance status 0 to 2\n* American Society of Anesthesiologist (ASA) score ≤2\n* Normal renal function: Calculated Creatinine Clearance ≥50ml\u002Fmin（by Cockcroft-Gault formula）and functional contralateral kidney by differential renal isotope scan\n* Normal bone marrow and hepatic function.\n* Contraception was needed for female patients of child-bearing age, or male patients whose partner had child-bearing age\n* expected life expectancy longer than 5 years\n* Written consent form was given prior to treatment\n* Can safely be treated by radiotherapy and surgery\n\nExclusion Criteria:\n\n* metastatic disease\n* Tumor was previously treated by radiotherapy\n* Involvement of liver, pancreatic head or duodenum",{"count":57,"type":20},50,[23],"To investigate the feasibility and peri-operative complications of preoperative hypo-fractionated radiotherapy followed by surgery for retroperitoneal sarcoma",[61,27,29,30,62],"Soft Tissue Sarcoma","Stereotactic Ablative Radiotherapy",[64,32,33,34,36],"stereotactic ablative radiotherapy","RECRUITING","2025-12-04",{"date":68,"type":41},"2025-12-11",{"date":70,"type":41},"2022-01-01",{"date":72,"type":20},"2027-12-31",{"name":46,"class":47},""]